BioAtla Investor Presentation Deck slide image

BioAtla Investor Presentation Deck

Leadership Team Jay Short, Ph.D. Chairman, CEO and Cofounder STRATAGENE DIVERSA HARNESSING THE POWER OF ENZYMES bicatla life technologies Richard Waldron, M.B.A. Chief Financial Officer SYNTHETIC GENOMICS INTREXON GeneMedicine, Inc. COWEN Cathy Chang, Ph.D. Sr. VP, Research & Development DIVERSA HARNESSING THE POWER OF ENZYMES STRATAGENE AND COMPANY Philippe Martin, M.S., M.B.A. Chief of Clinical Dev & Operations Colame Aventis op Schering-Plough Celgene William Boyle, Ph.D. Sr. Research Fellow Anaptys Bio AMGEN salk Where cures begin. Sheri Lydick Sr. VP, Commercial Strategy STRATAGENE Celgenel Bristol Myers Squibb ALTANA Monica Sullivan Sr. VP, Intellectual Property & Contracts DIVERSA BARNESSING THE POWER OF ENZYMES CapalP senomyx Eric Sievers, M.D. Chief Medical Officer OSeattleGenetics ZYMOGENETICS A Bristol-Myers Squibb Company Susie Melody Sr. VP, Human Resources Biogen. BCG BioAtla| Overview FRED HUTCH CURES START HERE 4
View entire presentation